A few reports indicated that NRP-1 downregulation or antagonism inhibited migration and enhanced chemosensitivity in non-small cell lung, kidney or prostate cancer [49] and osteosarcoma cells [50]. This evidence concerns the gene NRP1 and Familial prostate cancer.